<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624542</url>
  </required_header>
  <id_info>
    <org_study_id>NCV for PFPS</org_study_id>
    <nct_id>NCT04624542</nct_id>
  </id_info>
  <brief_title>Relation Between Femoral Nerve Conduction Velocity and Its Mechanosensitivity Changes Among Patellofemoral Pain Syndrome</brief_title>
  <official_title>Relation Between Femoral Nerve Conduction Velocity and Its Mechanosensitivity Changes Among Individual With Patellofemoral Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. to investigate the relation between NCV of femoral nerve and other dependent variables&#xD;
           such as ( pain &amp; limited hip extension ROM )in patients with PFPS .&#xD;
&#xD;
        2. to predict using the NCV as a method for assessment femoral nerve mechanosensitivity in&#xD;
           those with PFPS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patellofemoral pain syndrome (PFPS) is considered one of the most common condition affecting&#xD;
      young active populations, it accounts for about 40% of individuals complaining from knee&#xD;
      pain.PFPS is the anterior or retro patellar pain that can be precipitated by some daily&#xD;
      activities such as ascending and descending stairs, kneeling, squatting or performing&#xD;
      everyday tasks. Individuals with PFPS can experience a history of cracking or popping sounds&#xD;
      when changing position or climbing stairs and also experience pain during repeated knee&#xD;
      flexion. In a previous study conducted by Jensen et al .(2008),they observed that individuals&#xD;
      with PFPS experienced symptoms that are related to neural compromise like patellar numbness&#xD;
      and reduced ability to differentiate between different thermal stimulus .so PFPS may be&#xD;
      related to neurological impairments or dysfunction.&#xD;
&#xD;
      Femoral slump test can be used in examining the neurodynamic responses in individuals with&#xD;
      anterior knee pain which has a specificity of more than 75% in testing neural&#xD;
      mechanosensitivity In a study conducted by Lin et al (2014) that examine the hip extension&#xD;
      range of motion (ROM) and mechanical sensitivity of femoral nerve as a neurodynamic response&#xD;
      in individuals with PFPS , they proposed that 30% of them have decrease hip extension ROM and&#xD;
      increased mechanosensitivity comparison with healthy individuals. The current management of&#xD;
      the patellofemoral pain support using open- and closed-chain exercises, strengthening,&#xD;
      stretching, aerobic exercise, patellofemoral and tibiofemoral mobilizations, patellar taping,&#xD;
      highintensity NMES, neuromuscular training, and gait retraining as a multi modal treatment&#xD;
      for PFPS. Despite these methods result in significant improvement, other few patients&#xD;
      reported some residual symptoms Hung et al .,(2015) have encouraged that using the femoral&#xD;
      nerve mobilization as a neurodynamic management for treating PFPS patients especially those&#xD;
      with postive femoral slump test , and testing the hip extension range of motion as a&#xD;
      reference of improvement previous studies reported the presence of neurogenic dysfunction&#xD;
      model to PFPS but most of these scientific researches lack the presence of the gold standard&#xD;
      and objective method for identifying the neurogenic patellofemoral pain&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>the patellofemoral pain</measure>
    <time_frame>6 months</time_frame>
    <description>pain will be measured by using the Pain numeric rating scale (NRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>range of hip extension</measure>
    <time_frame>6 month</time_frame>
    <description>ROM will be measured using universal goniometer</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Patello Femoral Syndrome</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <description>Thirty individuals diagnosed with unilateral chronic PFPS from both genders and age between 18-35 years who will be referred from an orthopedic surgeon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>-30 healthy active individuals ranging from 18-36 yrs as a controlled group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electromyographic device</intervention_name>
    <description>the EMG machine will be used to measure NCV of femoral nerve within individuals with PFPS</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants recruitment to this study will be conducted over 2 steps process. In the first&#xD;
        step, all participants in the experimental group that will be referred from an orthopedic&#xD;
        surgeon with diagnosis of unilateral PFPS to the outpatient clinic at Cairo University&#xD;
        hospital at kasr el ainy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The inclusion criteria screened by the clinicians was pain during patellar palpation.&#xD;
             In addition, subjects needed to fulfill all of the following requirements to be&#xD;
             included in the PFP group:&#xD;
&#xD;
               1. Patient reporting symptoms of insidious onset and duration of at least 1 month&#xD;
                  (de Oliveira et al .,2016)&#xD;
&#xD;
               2. Peri- or retropatellar pain during at least 2 of the following activities:&#xD;
                  squatting, prolonged sitting, kneeling, running, jumping and climbing stairs&#xD;
                  (Vegstein et al., 2019)&#xD;
&#xD;
               3. Worst pain level in the previous month of up to 3cm on a 10cm numerical rating&#xD;
                  scale (NRS). (de Oliveira et al .,2016)&#xD;
&#xD;
               4. BMI 25-30 kg/cm2 (Nouri F et al .,2019)&#xD;
&#xD;
               5. Showing 2 or more positive signs on the following clinical tests:&#xD;
&#xD;
        Clarke's sign, Waldron test, active patellar grind test, patellar compression test ,and&#xD;
        palpation of the medial/lateral articular border of the patella.(hung et al., 2015) To be&#xD;
        included in the control group CG, participants could not present any signs or symptoms of&#xD;
        PFP or other musculoskeletal conditions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) inflammatory process of lower limb (Lin et al., 2014 ) 2) patellar tendon or&#xD;
             meniscus tears (hung et al., 2015) 3) bursitis and ligament tears (hung et al., 2015)&#xD;
             4) Those who had undergone knee surgery, oral steroids and knee injection were&#xD;
             excluded from this study (Vegstein et al., 2019) 5) lower back dysfunction such as&#xD;
             disc lesion , sciatica or spondylolisthesis (Lin et al., 2014 ) 6) participants that&#xD;
             had undergone physiotherapy during the preceding 6 months (de Oliveira et al .,2016)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>nabil ab abdo</last_name>
    <role>Study Director</role>
    <affiliation>PHD faculty of physical therapy Cairo university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ramez fd fahim, Bachelor</last_name>
    <phone>201211553069</phone>
    <email>ramezfahim1993@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>nabil ab abdo, PHD</last_name>
    <phone>201144259011</phone>
  </overall_contact_backup>
  <reference>
    <citation>Fredericson M, Yoon K. Physical examination and patellofemoral pain syndrome. Am J Phys Med Rehabil. 2006 Mar;85(3):234-43. Review.</citation>
    <PMID>16505640</PMID>
  </reference>
  <reference>
    <citation>Fredericson M, Powers CM. Practical management of patellofemoral pain. Clin J Sport Med. 2002 Jan;12(1):36-8.</citation>
    <PMID>11854587</PMID>
  </reference>
  <reference>
    <citation>Jensen R, Kvale A, Baerheim A. Is pain in patellofemoral pain syndrome neuropathic? Clin J Pain. 2008 Jun;24(5):384-94. doi: 10.1097/AJP.0b013e3181658170.</citation>
    <PMID>18496302</PMID>
  </reference>
  <reference>
    <citation>Jensen R, Hystad T, Kvale A, Baerheim A. Quantitative sensory testing of patients with long lasting Patellofemoral pain syndrome. Eur J Pain. 2007 Aug;11(6):665-76. Epub 2007 Jan 3.</citation>
    <PMID>17204440</PMID>
  </reference>
  <reference>
    <citation>Eliav E, Benoliel R, Tal M. Inflammation with no axonal damage of the rat saphenous nerve trunk induces ectopic discharge and mechanosensitivity in myelinated axons. Neurosci Lett. 2001 Sep 21;311(1):49-52.</citation>
    <PMID>11585565</PMID>
  </reference>
  <reference>
    <citation>Sanchis-Alfonso V, Rosell√≥-Sastre E. Immunohistochemical analysis for neural markers of the lateral retinaculum in patients with isolated symptomatic patellofemoral malalignment. A neuroanatomic basis for anterior knee pain in the active young patient. Am J Sports Med. 2000 Sep-Oct;28(5):725-31.</citation>
    <PMID>11032232</PMID>
  </reference>
  <reference>
    <citation>Heintjes E, Berger MY, Bierma-Zeinstra SM, Bernsen RM, Verhaar JA, Koes BW. Exercise therapy for patellofemoral pain syndrome. Cochrane Database Syst Rev. 2003;(4):CD003472. Review. Update in: Cochrane Database Syst Rev. 2015;1:CD003472.</citation>
    <PMID>14583980</PMID>
  </reference>
  <results_reference>
    <citation>Smith BE, Selfe J, Thacker D, Hendrick P, Bateman M, Moffatt F, Rathleff MS, Smith TO, Logan P. Incidence and prevalence of patellofemoral pain: A systematic review and meta-analysis. PLoS One. 2018 Jan 11;13(1):e0190892. doi: 10.1371/journal.pone.0190892. eCollection 2018. Review.</citation>
    <PMID>29324820</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Nabil Abdo Abdellah Mohamed</investigator_full_name>
    <investigator_title>lecturer of orthopedic physiotherapy /faculty of physical therapy cairo university</investigator_title>
  </responsible_party>
  <keyword>femoral nerve conduction velocity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Patellofemoral Pain Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>the data include his /her name ,age, sex , demographic data including (height,weight &amp;BMI ) and the phone number and address with ID number</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

